• Aptevo Therapeutics published a medical research presentation on multispecific antibody-like molecules designed to overcome immunosuppression in solid tumors.
• In cell-culture studies, APVO451 and APVO452 showed greater tumor-cell killing than bispecific controls in an immunosuppressive tumor microenvironment.
• APVO451 also stimulated exhausted T cells to kill tumor cells.
• APVO711 combined PD-L1 blockade with tumor-dependent CD40 activation, enhancing tumor-cell killing when used with T-cell engagers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief on November 07, 2026, and is solely responsible for the information contained therein.